关于山东三元生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"）持续 督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公 告格式》等法律法规的相关规定，对三元生物 2023 年度募集资金存放与使用情 况进行了核查，核查的具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）核准，并经深圳证券交 易所同意,公司向社会公众公开发行人民币普通股（A 股）3,372.10 万股，每股面 值为人民币 1.00 元，发行价格为人民币 109.30 元/股，募集资金总额为人民币 ...

深 圳 证 券 交 易 所 创业板监管函〔2024〕第 25 号 山东三元生物科技股份有限公司董事会： 2022 年 1 月 28 日，你公司董事会审议通过拟使用不超 过 33 亿元暂时闲置的募集资金进行现金管理的议案，并于 当日使用暂时闲置募集资金 5 亿元进行现金管理，但你公司 直至 2022 年 2 月 15 日才披露上述事项。 你公司的上述行为违反了本所《创业板股票上市规则》 （2020 年 12 月修订）第 1.4 条和《上市公司自律监管指引第 2 号——创业板上市公司规范运作》第 6.3.9 条的规定。请 你公司董事会充分重视上述问题，吸取教训，及时整改，杜 绝上述问题的再次发生。 我部提醒你公司：上市公司必须按照国家法律、法规和 本所《创业板股票上市规则》，认真和及时地履行信息披露 义务。上市公司的董事会全体成员必须保证信息披露内容真 1 关于对山东三元生物科技股份有限公司的 监管函 特此函告。 深圳证券交易所 创业板公司管理部 2024 年 3 月 4 日 2 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏， 并就其保证承担个别和连带的责任。 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 29 日 收到中国证券监督管理委员会山东监管局出具的《关于对山东三元生物科技股份 有限公司采取出具警示函措施的决定》〔2024〕26 号（以下简称"《警示函》"） 现将相关内容公告如下： 一、《警示函》的内容 山东三元生物科技股份有限公司： 证券代码：301206 证券简称：三元生物 公告编号：2024-018 山东三元生物科技股份有限公司 关于收到山东监管局出具警示函的公告 特此公告 山东三元生物科技股份有限公司 2022 年 1 月 28 日，你公司使用暂时闲置募集资金 5 亿元进行现金管理。该 事项未在董事会审议后 2 个交易日内公告，直至 2022 年 2 月 15 日才予以披露。 上述行为违反了《上市公司信息披露管理办法》（证监会令第 182 号）第三 条第一款、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》（证监会公告〔2022〕15 号）第八条第二款的规定。根据《上市公司信息 披露管理办法》（证监会令第 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-015 山东三元生物科技股份有限公司 关于控股股东、实际控制人、董事长及高级管理人员 增持公司股份计划实施进展的公告 公司控股股东、实际控制人、董事长聂在建先生；总经理程保华先生保证向 本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 1 / 5 1、增持计划主体：公司控股股东、实际控制人、董事长聂在建先生；总经 理程保华先生。 2、增持计划实施前，聂在建先生直接持有公司股份 92,946,000 股，占公司 当前总股本的 45.94%；程保华先生直接持有公司股份 2,028,000 股，占公司当前 总股本的 1.00%。 3、截至本公告披露前 12 个月内，聂在建先生、程保华先生未披露过增持计 划。 4、截至本公告披露前 6 个月内，聂在建先生、程保华先生未减持公司股份， 亦未披露减持计划。 二、增持计划的主要内容 特别提示： 1、山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 7 日在巨潮资讯网 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-014 山东三元生物科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、持有山东三元生物科技股份有限公司（以下简称"公司"或"三元生物"） 股份 92,946,000 股（占公司当前总股本的 45.94%）的控股股东、实际控制人、 董事长聂在建先生；持有公司股份 2,028,000 股（占公司当前总股本的 1.00%） 的总经理程保华先生基于对公司未来持续稳定发展和长期投资价值的信心，拟使 用自有资金计划自本公告披露之日起 6 个月内，通过深圳证券交易所系统以集中 竞价交易或大宗交易方式增持公司股份，合计拟增持金额不低于人民币 850 万元 且不超过人民币 1100 万元。 2、本次增持计划不设置价格区间，增持主体将基于对公司股票价值的合理 判断，结合公司股票价格波动情况及资本市场整体趋势，在增持计划期间内择机 实施增持。 公司于近日收到控股股东、实际控制人、董事长聂在建先生、总经理程保华 先生出具的《关于增持公司股份计划的告知函》，现将有关情况公告如下： 一、计划增持 ...

Financial Performance - The company's revenue for the first half of 2023 was ¥235.31 million, a decrease of 48.54% compared to ¥457.28 million in the same period last year[26]. - The net profit attributable to shareholders was ¥33.32 million, down 72.04% from ¥119.18 million year-on-year[26]. - The net cash flow from operating activities was ¥245.78 thousand, a significant decline of 99.24% compared to ¥32.36 million in the previous year[26]. - Basic and diluted earnings per share were both ¥0.16, representing a decrease of 73.77% from ¥0.61 in the same period last year[26]. - The total assets at the end of the reporting period were ¥4.71 billion, a decrease of 3.24% from ¥4.87 billion at the end of the previous year[26]. - The net assets attributable to shareholders decreased by 2.34% to ¥4.51 billion from ¥4.62 billion at the end of the previous year[26]. - The company's gross profit margin for the first half of 2023 was only 0.12%, a sharp decline from 41.99% in 2021 and 14.06% in 2022, reflecting increased cost pressures[120]. - The company's production capacity utilization rate was below 50% in the first half of 2023, indicating a risk of overcapacity in the erythritol market[123]. Market and Industry Trends - The company operates in the functional sugar industry, focusing on the research, production, and sales of products like erythritol and allulose[34]. - The functional sugar market has seen a surge in demand due to the rising trend of sugar reduction, with erythritol becoming a widely used sweetener across various sectors[35]. - Recent government policies support the functional sugar industry, promoting health-conscious consumption and encouraging the use of low-sugar alternatives[39]. - The "Healthy China 2030" initiative emphasizes the importance of health and nutrition, which aligns with the company's product offerings[40]. - The competitive landscape has intensified, with many new entrants in the erythritol market, impacting overall profitability[37]. - The anticipated growth in the sugar-free beverage market will further drive the downstream demand for erythritol[44]. Research and Development - The company is committed to innovation in product development to meet the evolving consumer preferences for healthier options[35]. - The company focuses on the research and development of functional sugars, particularly erythritol and allulose, to meet the growing demand for health-oriented products[47]. - The company has developed a new strain of yeast that can increase the purity of residual erythritol from below 50% to over 70%, and further to 80% after repeated trials, enhancing extraction efficiency[70]. - Research and development investment amounted to ¥21,561,358.95, a slight decrease of 2.85% from ¥22,192,798.83 in the previous year[79]. Corporate Governance and Shareholder Relations - The company emphasizes the protection of shareholder rights and has established a robust governance structure to enhance operational transparency[136]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[5]. - The controlling shareholder and senior management have committed to not transferring or entrusting the management of their shares for 36 months post-IPO[141]. - The company has established a clear framework for share management to align with corporate governance standards[141]. - The company has committed to improving its profit distribution policy to enhance investor returns, particularly focusing on independent directors and minority shareholders' feedback[147]. Cash Management and Fund Utilization - The company plans to use up to RMB 2.4 billion of temporarily idle raised funds for cash management, effective for 12 months from the approval date[170]. - The company has incurred a net income of RMB 1,232.49 million from interest on the raised funds[98]. - The total amount raised from the initial public offering was CNY 368,570.53 million, with a net amount of CNY 354,664.46 million after deducting issuance costs of CNY 13,906.07 million[102]. - The company will strengthen fundraising management to ensure that the raised funds are used for their intended purposes and achieve expected benefits[147]. Strategic Outlook - The company provided a positive outlook for the second half of 2023, expecting continued growth and market expansion[142]. - The company aims to expand its market presence in key regions, targeting a 15% increase in market share by the end of 2024[142]. - The company is exploring strategic acquisitions to enhance its market position and product offerings[142]. - The company plans to enhance its product range by accelerating the development of new products such as allulose and high-quality stevia sugar, aiming to diversify its offerings[115]. Compliance and Regulatory Matters - The company has updated its pollutant discharge permit, valid from August 24, 2022, to August 23, 2027, indicating compliance with environmental regulations[133]. - The company adheres to ISO 14001 environmental management standards, ensuring sustainable production practices[134]. - The semi-annual financial report for 2023 has not been audited yet, which is standard practice for this period[154]. - The company has maintained a clean integrity status with no penalties or rectifications required[156].

Financial Performance - Revenue for Q3 2023 reached ¥115,878,873.28, an increase of 9.23% compared to the same period last year, but a decrease of 37.66% year-to-date[4] - Net profit attributable to shareholders for Q3 2023 was ¥8,355,862.63, down 73.87% year-on-year, and down 72.43% year-to-date[4] - Basic earnings per share for Q3 2023 was ¥0.04, a decrease of 75.00% compared to the same period last year[4] - The total operating revenue for the third quarter of 2023 was CNY 351,192,635.35, a decrease of 37.5% compared to CNY 563,363,651.68 in the same period last year[25] - The net profit for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% compared to CNY 151,155,941.78 in Q3 2022[26] - Operating profit for Q3 2023 was CNY 44,871,999.14, down 73.6% from CNY 169,888,387.28 in Q3 2022[26] - The total comprehensive income for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% from CNY 151,155,941.78 in the same quarter last year[27] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.21, compared to CNY 0.76 in Q3 2022[27] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,755,601,460.68, a decrease of 2.35% from the end of the previous year[4] - The total assets as of September 30, 2023, were CNY 4,755,601,460.68, down from CNY 4,869,919,341.29 at the beginning of the year, a decrease of 2.3%[23] - The total liabilities decreased to CNY 234,780,503.70 from CNY 249,143,294.88, indicating a reduction of 5.8%[23] - The company's equity attributable to shareholders decreased to CNY 4,520,820,956.98 from CNY 4,620,776,046.41, a decline of 2.2%[23] Cash Flow - Cash flow from operating activities for the first nine months of 2023 was ¥21,942,222.52, down 75.73% year-on-year due to increased market competition[11] - Cash flow from operating activities generated a net amount of CNY 21,942,222.52, significantly lower than CNY 90,426,851.62 in the previous year[30] - The company's cash and cash equivalents decreased to CNY 117,966,133.78 from CNY 489,042,093.26 at the beginning of the year, representing a decline of 75.9%[21] - The company experienced a cash and cash equivalents net decrease of CNY -363,462,995.99, compared to an increase of CNY 256,890,519.32 in Q3 2022[30] - Total cash flow from investment activities was negative at CNY -251,828,518.11, compared to CNY -3,282,248,061.08 in the same period last year[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,770[13] - The total number of restricted shares at the beginning of the period was 92,946,000, with no shares released during the period, maintaining the same amount at the end[16] - 24,780,000 shares were released from restrictions for Shandong Luxin Qisheng Investment Management Co., Ltd. on February 10, 2023[16] - The company has a total of 12,852,000 restricted shares held by the shareholder Moxian, which were also released on February 10, 2023[16] - The management's locked shares include 2,160,000 shares for Li Dechun, with 25% of the total shares eligible for circulation each year during the tenure[16] - The shareholder Wang Meihua holds 2,745,395 shares, with 91,000 shares held through a regular account and 2,653,995 shares through a margin account[16] - The company reported a total of 5,400,000 restricted shares held by Shandong Kexin Venture Capital Co., Ltd., which were released on February 10, 2023[16] - The shareholder Zhang Yanjie has 2,206,697 restricted shares, all of which were released on February 10, 2023[16] - The total number of restricted shares held by the management team is subject to a 25% annual release during their tenure[16] - The company has a total of 1,137,258 restricted shares held by the shareholder Wang Meihua, which are also subject to the same release conditions[16] - The company has not disclosed any relationships or agreements among the top ten unrestricted shareholders[16] Operational Changes - The company decided to cancel the plan to use CNY 790 million of raised funds for permanent working capital supplementation due to lower than expected working capital needs[19] - The company held meetings to approve changes to its business scope and amendments to its articles of association to align with current operational needs[18] Other Income - Investment income for the first nine months of 2023 was ¥83,866,978.78, an increase of 39.56% compared to the same period last year[10] - Other income for the first nine months of 2023 was ¥821,692.01, a decrease of 87.55% year-on-year due to reduced government subsidies[10] Research and Development - Research and development expenses increased to CNY 36,626,985.64, up 14.5% from CNY 31,870,190.36 in the same period last year[26]

Financial Performance - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - Basic and diluted earnings per share fell by 26.09% to ¥0.51 from ¥0.69 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase from CNY 263,493,075.06 in the previous period[20] - Net profit for Q1 2022 was CNY 62,765,994.16, down from CNY 69,465,064.33 in the previous period, indicating a decrease of approximately 9.7%[21] - Earnings per share for Q1 2022 were CNY 0.51, compared to CNY 0.69 in the previous period, showing a decline[22] Cash Flow - The net cash flow from operating activities dropped significantly by 84.24% to ¥20,443,976.73, down from ¥129,686,530.82 in the previous year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[25] - Total cash inflow from financing activities was ¥3,573,401,313.01, while cash outflow was ¥22,336,495.47, resulting in a net cash flow of ¥3,551,064,817.54[26] - The net increase in cash and cash equivalents for the period was ¥9,191,788.52, compared to an increase of ¥83,423,153.69 in the previous year[26] - The total cash and cash equivalents at the end of the period stood at ¥267,134,010.23, up from ¥141,186,753.95 at the end of Q1 2021[26] - The company reported cash inflow from operating activities totaling ¥312,922,891.80, an increase from ¥290,470,739.70 in the same period last year[25] - Cash outflow for purchasing goods and services was ¥266,221,244.95, significantly higher than ¥139,392,617.05 in Q1 2021[25] - The company recorded cash inflow from investment activities of ¥477,900.00, while cash outflow was ¥3,563,181,945.45, leading to a net cash flow of -¥3,562,704,045.45[25] - The company received ¥3,567,762,730.40 from investment activities, indicating strong capital inflow during the quarter[26] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 compared to ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in the previous period[18] - The company's equity attributable to shareholders was CNY 4,654,908,120.59, significantly higher than CNY 1,045,328,564.67 in the previous period[18] - Deferred income tax liabilities increased to CNY 25,228,040.35 from CNY 23,025,951.67 in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21.906 million[11] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[11] Investment and Subsidiary Activities - The company raised a total of RMB 3,685,705,300 from the public offering of 33.721 million shares at RMB 109.3 per share[13] - The net amount raised after deducting issuance costs was RMB 3,546,644,640.40[13] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million[14] Other Financial Metrics - Cash received from tax refunds increased by 47.42%, primarily due to an increase in VAT refunds during the reporting period[8] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to rising raw material prices and a shift in payment methods[8] - Other payables increased by 44.69%, mainly due to an increase in customer deposits for yeast mud sales[9] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, slightly down from CNY 11,579,638.16 in the previous period[21] Audit Status - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[27]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company's operating revenue for the reporting period was approximately ¥457.28 million, a decrease of 41.89% compared to the same period last year[26]. - The net profit attributable to shareholders was approximately ¥119.18 million, down 50.93% year-on-year[26]. - The net cash flow from operating activities was approximately ¥32.36 million, reflecting a significant decline of 88.16% compared to the previous year[26]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-over-year growth of 20%[111]. - The company reported a net profit for the first half of 2022 of CNY 119,527,796.34, a decrease of 50.7% compared to CNY 242,889,853.19 in the same period of 2021[184]. - The total revenue for the first half of 2022 was CNY 5,557,800,000, representing a year-on-year increase of 33.7%[194]. Profitability and Margins - The gross profit margin improved to 35%, up from 30% in the same period last year[17]. - The company achieved a gross margin of 18.33% for erythritol, down 22.37% year-on-year, with revenue decreasing by 47.36%[56]. - The overall gross profit margin decreased from 42.27% in 2020 to 21.30% in the first half of 2022, reflecting challenges in maintaining high profitability[89]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[110]. - The company reported a significant increase in retained earnings, contributing to a stronger equity position[193]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[17]. - Investment in R&D increased by 25% year-on-year, focusing on innovative biotechnology solutions[110]. - The company is focusing on R&D in synthetic biology and has established a wholly-owned subsidiary to enhance its technological capabilities[49]. - The company has set a target to increase its R&D investment to 10% of total revenue, emphasizing the importance of innovation in its growth strategy[117]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share by 2025[17]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[110]. - The company plans to focus on market demand by vigorously developing new technologies and products, aiming to launch high-value-added products that meet market needs[90]. - A strategic acquisition of a local biotech firm is anticipated to enhance product offerings and accelerate growth[110]. Operational Efficiency - The conversion rate of raw materials to end products improved to 85% in the reporting period[15]. - The company has adopted a procurement model based on "production-driven ordering and price comparison," ensuring efficient supply chain management[34]. - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[110]. - The company aims to improve its operational efficiency, targeting a reduction in production costs by 5% through process optimization[111]. Shareholder and Capital Management - No cash dividends or stock bonuses will be distributed for this fiscal year[5]. - The company has not reported any changes in fundraising projects during the reporting period[76]. - The company has a commitment to not transfer or delegate the management of shares held prior to the public offering for 12 months[109]. - The company will prioritize measures such as stock repurchase, shareholding increase by controlling shareholders, and management stock purchases to stabilize the stock price[112]. Risk Management - The company faces risks related to supply chain disruptions and has implemented measures to mitigate these risks[4]. - The company faced a risk of intensified market competition in the erythritol industry, which could lead to price declines and increased sales expenses[83]. - The company acknowledges the existence of internal and external risks that may affect future profits, despite measures to protect shareholder interests[115]. Compliance and Governance - The company adheres to the ISO14001 environmental management system standards, ensuring compliance with environmental protection laws and regulations[102]. - The management emphasized the importance of adhering to regulatory compliance and maintaining shareholder trust during the upcoming growth phase[111]. - The company will publicly disclose reasons for not implementing stabilization measures if conditions are met but not acted upon, and will apologize to investors[112]. Assets and Liabilities - The total assets at the end of the reporting period reached approximately ¥4.87 billion, an increase of 198.26% from the end of the previous year[26]. - The company's total liabilities decreased to CNY 297,710,441.18 from CNY 588,828,870.18, indicating a reduction of approximately 49.6%[174]. - The equity attributable to the parent company increased significantly to CNY 4,576,268,962.21 from CNY 1,045,328,564.67, marking an increase of around 338.5%[174].

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company's total revenue for the current period was CNY 563,363,651.68, a decrease of approximately 56.7% compared to CNY 1,305,360,240.59 in the same period last year[27] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in Q3 2021[28] - Operating profit for the quarter was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, the total assets of Shandong Sanyuan Biotechnology Co., Ltd. amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[23] - The total liabilities of the company as of September 30, 2022, were CNY 189,942,474.74, down from CNY 588,828,870.18, a reduction of approximately 67.8%[25] Equity and Shareholder Information - The company reported a significant increase in total equity attributable to shareholders, which reached CNY 4,608,245,346.85, up 340.84% from the previous year[4] - The equity attributable to the owners of the parent company increased to CNY 4,608,245,346.85 from CNY 1,045,328,564.67, reflecting a growth of about 340.5%[25] - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, totaling 92,946,000 shares[14] - The company completed a capital increase from capital reserves, increasing the total share capital from 134,883,800 shares to 202,325,700 shares, with a distribution of 5 shares for every 10 shares held[19] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, down 82.62% compared to the previous year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 in the previous year[28] Operational Changes - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its credibility and operational efficiency in international trade[21] - The company has changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, indicating a strategic shift in its auditing approach[20] - The company has not disclosed any related party relationships among the top ten shareholders[15] - The company has not reported any new product developments or market expansion strategies during the reporting period[18] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, indicating a reduction of approximately 76.3%[23] - Inventory levels decreased to CNY 73,203,380.23 from CNY 112,157,402.58, representing a decline of about 34.7%[24] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2022, were CNY 514,413,874.36, slightly down from CNY 515,719,690.44 at the beginning of the year[23] - The company reported a total cash and cash equivalents balance of CNY 514,832,741.03 at the end of the quarter, compared to CNY 254,249,794.17 at the end of Q3 2021[31]